NCT04390178View on ClinicalTrials.gov

Convalescent Plasma as Treatment for Acute Coronavirus Disease (COVID-19)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

April 10, 2020

Primary Completion Date

June 30, 2020

Study Completion Date

December 31, 2020

Conditions
COVID-19
Interventions
BIOLOGICAL

SARS-CoV-2 convalescent plasma

Treatment with convalescent plasma (180-200ml) from individuals who have recovered from SARS-CoV-2 infection

Trial Locations (1)

182 57

Danderyd Hospital, Danderyd

All Listed Sponsors
collaborator

Danderyd Hospital

OTHER

collaborator

Karolinska Institutet

OTHER

collaborator

Karolinska University Hospital

OTHER

lead

Joakim Dillner

OTHER

NCT04390178 - Convalescent Plasma as Treatment for Acute Coronavirus Disease (COVID-19) | Biotech Hunter | Biotech Hunter